Immunicom Presents Promising Preliminary Data from Immunopheresis® Studies in Late-Stage Cancer Patients at JCA-AACR 2021
Retrieved on:
Tuesday, September 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Education, Association, American Association, Immune system, Patient, Renal cell carcinoma, Japanese Cancer Association, Large-cell lung carcinoma, Jagiellonian University, Degenerative disease, Research, AACR, Science, American Association for Cancer Research, Antibody, ISO, Conference, Medicine, Toxicity, NSCLC, Radiation, Diagnosis, CE marking, Cancer, Principal investigator, Immunotherapy, Food, Bristol Myers Squibb, FDA, Protein, Japanese Association of Medical Sciences, Cytokine, Certification, Quality of life, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TNBC, Technology, Doctor of Philosophy, Risk, Clinical trial, Sheba Medical Center, JCA, Cancer Science, Multimedia, Pharmaceutical industry, Vaccine, Medical device, Immunicom, JCA and AACR, IMMUNICOM, JCA AND AACR
Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
Key Points:
- Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
- Immunicoms ongoing clinical trials are in the most difficult to treat, late-stage cancer patients.
- Immunicoms novel Immunopheresis therapy uses its proprietary subtractive LW-02 column to selectively remove immune-suppressive cytokines produced by cancer tumors.
- Standard cancer treatments are surgery, radiation or those that typically require the infusion of drugs, antibodies or proteins into the patient.